Roles of linear ubiquitinylation, a crucial regulator of NF-κB and cell death, in the immune system

Immunological Reviews

Volumn 266, Issue 1, 2015, Pages 175-189

  Sasaki, Katsuhiro ^a   Iwai, Kazuhiro ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cell death; Inflammation; Linear ubiquitinylation; LUBAC; NF B; Ubiquitin

Indexed keywords

HEME OXIDIZED IRP2 LIGASE 1L; HOIL 1 INTERACTING PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLAMMASOME; INTERLEUKIN 1BETA; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN OTULIN; RETINOIC ACID INDUCIBLE PROTEIN I; SHANK ASSOCIATED RH DOMAIN INTERACTING PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UBIQUITIN; UBIQUITIN THIOLESTERASE; UNCLASSIFIED DRUG; CARRIER PROTEIN; HOIL-1L PROTEIN, MOUSE; MULTIPROTEIN COMPLEX; NERVE PROTEIN; RNF31 PROTEIN, HUMAN; SHARPIN; UBIQUITIN PROTEIN LIGASE;

ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; CARCINOGENESIS; CATALYSIS; CELL DEATH; CELL FUNCTION; CHRONIC INFLAMMATION; ENZYME ACTIVATION; GENE MUTATION; HUMAN; IMMUNE DEFICIENCY; IMMUNE SYSTEM; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN SUBUNIT; SIGNAL TRANSDUCTION; UBIQUITINATION; ANIMAL; GENETICS; IMMUNOLOGY; METABOLISM; MUTATION;

ANIMALS; B-LYMPHOCYTES; CARCINOGENESIS; CARRIER PROTEINS; CELL DEATH; HUMANS; IMMUNE SYSTEM; MULTIPROTEIN COMPLEXES; MUTATION; NERVE TISSUE PROTEINS; NF-KAPPA B; SIGNAL TRANSDUCTION; UBIQUITIN-PROTEIN LIGASES; UBIQUITINATION;

EID: 84931031608     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/imr.12308     Document Type: Article

References (148)

1. Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem 1998;67:425-479.
2. Thrower JS, Hoffman L, Rechsteiner M, Pickart CM. Recognition of the polyubiquitin proteolytic signal. EMBO J 2000;19:94-102.
3. Verma R, McDonald H, Yates JR 3rd, Deshaies RJ. Selective degradation of ubiquitinated Sic1 by purified 26S proteasome yields active S phase cyclin-Cdk. Mol Cell 2001;8:439-448.
4. Finley D. Recognition and processing of ubiquitin-protein conjugates by the proteasome. Annu Rev Biochem 2009;78:477-513.
5. Mukhopadhyay D, Riezman H. Proteasome-independent functions of ubiquitin in endocytosis and signaling. Science 2007;315:201-205.
6. Wickliffe K, Williamson A, Jin L, Rape M. The multiple layers of ubiquitin-dependent cell cycle control. Chem Rev 2009;109:1537-1548.
7. Zinngrebe J, Montinaro A, Peltzer N, Walczak H. Ubiquitin in the immune system. EMBO Rep 2014;15:28-45.
8. Ozkaynak E, Finley D, Varshavsky A. The yeast ubiquitin gene: head-to-tail repeats encoding a polyubiquitin precursor protein. Nature 1984;312:663-666.
9. Kimura Y, Tanaka K. Regulatory mechanisms involved in the control of ubiquitin homeostasis. J Biochem 2010;147:793-798.
10. Finley D, Ozkaynak E, Varshavsky A. The yeast polyubiquitin gene is essential for resistance to high temperatures, starvation, and other stresses. Cell 1987;48:1035-1046.
11. Catic A, Ploegh HL. Ubiquitin-conserved protein or selfish gene? Trends Biochem Sci 2005;30:600-604.
12. Deshaies RJ, Joazeiro CA. RING domain E3 ubiquitin ligases. Annu Rev Biochem 2009;78:399-434.
13. Scheffner M, Nuber U, Huibregtse JM. Protein ubiquitination involving an E1-E2-E3 enzyme ubiquitin thioester cascade. Nature 1995;373:81-83.
14. Ye Y, Rape M. Building ubiquitin chains: E2 enzymes at work. Nat Rev Mol Cell Biol 2009;10:755-764.
15. Lee I, Schindelin H. Structural insights into E1-catalyzed ubiquitin activation and transfer to conjugating enzymes. Cell 2008;134:268-278.
16. Kulathu Y, Komander D. Atypical ubiquitylation - the unexplored world of polyubiquitin beyond Lys48 and Lys63 linkages. Nat Rev Mol Cell Biol 2012;13:508-523.
17. Fu QS, Song AX, Hu HY. Structural aspects of ubiquitin binding specificities. Curr Protein Pept Sci 2012;13:482-489.
18. Hurley JH, Lee S, Prag G. Ubiquitin-binding domains. Biochem J 2006;399:361-372.
19. Komander D, Rape M. The ubiquitin code. Annu Rev Biochem 2012;81:203-229.
20. Chen ZJ, Sun LJ. Nonproteolytic functions of ubiquitin in cell signaling. Mol Cell 2009;33:275-286.
21. Dikic I, Wakatsuki S, Walters KJ. Ubiquitin-binding domains - from structures to functions. Nat Rev Mol Cell Biol 2009;10:659-671.
22. Hicke L, Schubert HL, Hill CP. Ubiquitin-binding domains. Nat Rev Mol Cell Biol 2005;6:610-621.
23. Komander D, Clague MJ, Urbe S. Breaking the chains: structure and function of the deubiquitinases. Nat Rev Mol Cell Biol 2009;10:550-563.
24. McGouran JF, Gaertner SR, Altun M, Kramer HB, Kessler BM. Deubiquitinating enzyme specificity for ubiquitin chain topology profiled by di-ubiquitin activity probes. Chem Biol 2013;20:1447-1455.
25. Tokunaga F, et al. Involvement of linear polyubiquitylation of NEMO in NF-κB activation. Nat Cell Biol 2009;11:123-132.
26. Tokunaga F, et al. SHARPIN is a component of the NF-κB-activating linear ubiquitin chain assembly complex. Nature 2011;471:633-636.
27. Kirisako T, et al. A ubiquitin ligase complex assembles linear polyubiquitin chains. EMBO J 2006;25:4877-4887.
28. Fiil BK, Gyrd-Hansen M. Met1-linked ubiquitination in immune signalling. FEBS J 2014;281:4337-4350.
29. Iwai K. Diverse ubiquitin signaling in NF-κB activation. Trends Cell Biol 2012;22:355-364.
30. Iwai K, Fujita H, Sasaki Y. Linear ubiquitin chains: NF-κB signalling, cell death and beyond. Nat Rev Mol Cell Biol 2014;15:503-508.
31. Boisson B, et al. Immunodeficiency, autoinflammation and amylopectinosis in humans with inherited HOIL-1 and LUBAC deficiency. Nat Immunol 2012;13:1178-1186.
32. Popovic D, Vucic D, Dikic I. Ubiquitination in disease pathogenesis and treatment. Nat Med 2014;20:1242-1253.
33. Turner GC, Varshavsky A. Detecting and measuring cotranslational protein degradation in vivo. Science 2000;289:2117-2120.
34. Peng J, et al. A proteomics approach to understanding protein ubiquitination. Nat Biotechnol 2003;21:921-926.
35. Gerlach B, et al. Linear ubiquitination prevents inflammation and regulates immune signalling. Nature 2011;471:591-596.
36. Ikeda F, et al. SHARPIN forms a linear ubiquitin ligase complex regulating NF-κB activity and apoptosis. Nature 2011;471:637-641.
37. Spratt DE, Walden H, Shaw GS. RBR E3 ubiquitin ligases: new structures, new insights, new questions. Biochem J 2014;458:421-437.
38. Stieglitz B, et al. Structural basis for ligase-specific conjugation of linear ubiquitin chains by HOIP. Nature 2013;503:422-426.
39. Smit JJ, Monteferrario D, Noordermeer SM, van Dijk WJ, van der Reijden BA, Sixma TK. The E3 ligase HOIP specifies linear ubiquitin chain assembly through its RING-IBR-RING domain and the unique LDD extension. EMBO J 2012;31:3833-3844.
40. Yagi H, et al. A non-canonical UBA-UBL interaction forms the linear-ubiquitin-chain assembly complex. EMBO Rep 2012;13:462-468.
41. Stieglitz B, Morris-Davies AC, Koliopoulos MG, Christodoulou E, Rittinger K. LUBAC synthesizes linear ubiquitin chains via a thioester intermediate. EMBO Rep 2012;13:840-846.
42. Walczak H, Iwai K, Dikic I. Generation and physiological roles of linear ubiquitin chains. BMC Biol 2012;10:23.
43. Reyes-Turcu FE, Ventii KH, Wilkinson KD. Regulation and cellular roles of ubiquitin-specific deubiquitinating enzymes. Annu Rev Biochem 2009;78:363-397.
44. Fiil BK, et al. OTULIN restricts Met1-linked ubiquitination to control innate immune signaling. Mol Cell 2013;50:818-830.
45. Keusekotten K, et al. OTULIN antagonizes LUBAC signaling by specifically hydrolyzing Met1-linked polyubiquitin. Cell 2013;153:1312-1326.
46. Takiuchi T, et al. Suppression of LUBAC-mediated linear ubiquitination by a specific interaction between LUBAC and the deubiquitinases CYLD and OTULIN. Genes Cells 2014;19:254-272.
47. Datta AB, Hura GL, Wolberger C. The structure and conformation of Lys63-linked tetraubiquitin. J Mol Biol 2009;392:1117-1124.
48. Rohaim A, Kawasaki M, Kato R, Dikic I, Wakatsuki S. Structure of a compact conformation of linear diubiquitin. Acta Crystallogr D Biol Crystallogr 2012;68(Pt 2):102-108.
49. Saggar S, et al. CYLD mutations in familial skin appendage tumours. J Med Genet 2008;45:298-302.
50. Sun SC. CYLD: a tumor suppressor deubiquitinase regulating NF-κB activation and diverse biological processes. Cell Death Differ 2010;17:25-34.
51. Trompouki E, Hatzivassiliou E, Tsichritzis T, Farmer H, Ashworth A, Mosialos G. CYLD is a deubiquitinating enzyme that negatively regulates NF-κB activation by TNFR family members. Nature 2003;424:793-796.
52. Harhaj EW, Dixit VM. Regulation of NF-κB by deubiquitinases. Immunol Rev 2012;246:107-124.
53. Massoumi R, Chmielarska K, Hennecke K, Pfeifer A, Fassler R. Cyld inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-κB signaling. Cell 2006;125:665-677.
54. Sasaki Y, et al. Defective immune responses in mice lacking LUBAC-mediated linear ubiquitination in B cells. EMBO J 2013;32:2463-2476.
55. Peltzer N, et al. HOIP deficiency causes embryonic lethality by aberrant TNFR1-mediated endothelial cell death. Cell Rep 2014;9:153-165.
56. HogenEsch H, Gijbels MJ, Offerman E, van Hooft J, van Bekkum DW, Zurcher C. A spontaneous mutation characterized by chronic proliferative dermatitis in C57BL mice. Am J Pathol 1993;143:972-982.
57. Gallardo Torres HI, Gijbels MJ, HegnEsch H, Kraal G. Chronic proliferative dermatitis in mice: neutrophil-endothelium interactions and the role of adhesion molecules. Pathobiology 1995;63:341-347.
58. Gijbels MJ, et al. Pathogenesis of skin lesions in mice with chronic proliferative dermatitis (cpdm/cpdm). Am J Pathol 1996;148:941-950.
59. Gijbels MJ, HogenEsch H, Blauw B, Roholl P, Zurcher C. Ultrastructure of epidermis of mice with chronic proliferative dermatitis. Ultrastruct Pathol 1995;19:107-111.
60. Liang Y, Seymour RE, Sundberg JP. Inhibition of NF-kappaB signaling retards eosinophilic dermatitis in SHARPIN-deficient mice. J Invest Dermatol 2011;131:141-149.
61. Potter CS, et al. Chronic proliferative dermatitis in Sharpin null mice: development of an autoinflammatory disease in the absence of B and T lymphocytes and IL4/IL13 signaling. PLoS ONE 2014;9:e85666.
62. Seymour R, Sundberg JP, Hogenesch H. Abnormal lymphoid organ development in immunodeficient mutant mice. Vet Pathol 2006;43:401-423.
63. HogenEsch H, Janke S, Boggess D, Sundberg JP. Absence of Peyer's patches and abnormal lymphoid architecture in chronic proliferative dermatitis (cpdm/cpdm) mice. J Immunol 1999;162:3890-3896.
64. Berger SB, et al. Cutting Edge: RIP1 kinase activity is dispensable for normal development but is a key regulator of inflammation in SHARPIN-deficient mice. J Immunol 2014;192:5476-5480.
65. Rivkin E, et al. The linear ubiquitin-specific deubiquitinase gumby regulates angiogenesis. Nature 2013;498:318-324.
66. Bignell GR, et al. Identification of the familial cylindromatosis tumour-suppressor gene. Nat Genet 2000;25:160-165.
67. Lee DA, Grossman ME, Schneiderman P, Celebi JT. Genetics of skin appendage neoplasms and related syndromes. J Med Genet 2005;42:811-819.
68. Hellerbrand C, Bumes E, Bataille F, Dietmaier W, Massoumi R, Bosserhoff AK. Reduced expression of CYLD in human colon and hepatocellular carcinomas. Carcinogenesis 2007;28:21-27.
69. Zhang J, et al. Impaired regulation of NF-κB and increased susceptibility to colitis-associated tumorigenesis in CYLD-deficient mice. J Clin Invest 2006;116:3042-3049.
70. Brummelkamp TR, Nijman SM, Dirac AM, Bernards R. Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-κB. Nature 2003;424:797-801.
71. Nikolaou K, Tsagaratou A, Eftychi C, Kollias G, Mosialos G, Talianidis I. Inactivation of the deubiquitinase CYLD in hepatocytes causes apoptosis, inflammation, fibrosis, and cancer. Cancer Cell 2012;21:738-750.
72. O'Donnell MA, et al. Caspase 8 inhibits programmed necrosis by processing CYLD. Nat Cell Biol 2011;13:1437-1442.
73. Xue L, Igaki T, Kuranaga E, Kanda H, Miura M, Xu T. Tumor suppressor CYLD regulates JNK-induced cell death in Drosophila. Dev Cell 2007;13:446-454.
74. Wright A, et al. Regulation of early wave of germ cell apoptosis and spermatogenesis by deubiquitinating enzyme CYLD. Dev Cell 2007;13:705-716.
75. Wang L, Du F, Wang X. TNF-α induces two distinct caspase-8 activation pathways. Cell 2008;133:693-703.
76. Compagno M, et al. Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma. Nature 2009;459:717-721.
77. Davis RE, Brown KD, Siebenlist U, Staudt LM. Constitutive nuclear factor κB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 2001;194:1861-1874.
78. Delhase M, Hayakawa M, Chen Y, Karin M. Positive and negative regulation of IκB kinase activity through IKKβ subunit phosphorylation. Science 1999;284:309-313.
79. Senftleben U, et al. Activation by IKKα of a second, evolutionary conserved. NF-κB signaling pathway. Science 2001;293:1495-1499.
80. Li ZW, et al. The IKKβ subunit of IκB kinase (IKK) is essential for nuclear factor κB activation and prevention of apoptosis. J Exp Med 1999;189:1839-1845.
81. Rothwarf DM, Zandi E, Natoli G, Karin M. IKK-γ is an essential regulatory subunit of the IκB kinase complex. Nature 1998;395:297-300.
82. Heissmeyer V, Krappmann D, Hatada EN, Scheidereit C. Shared pathways of IκB kinase-induced SCF(βTrCP)-mediated ubiquitination and degradation for the NF-κB precursor p105 and IκBα. Mol Cell Biol 2001;21:1024-1035.
83. Shirane M, Hatakeyama S, Hattori K, Nakayama K, Nakayama K. Common pathway for the ubiquitination of IκBα, IκBβ, and IκBε mediated by the F-box protein FWD1. J Biol Chem 1999;274:28169-28174.
84. Hatakeyama S, et al. Ubiquitin-dependent degradation of IκBα is mediated by a ubiquitin ligase Skp1/Cul 1/F-box protein FWD1. Proc Natl Acad Sci USA 1999;96:3859-3863.
85. Wu C, Ghosh S. β-TrCP mediates the signal-induced ubiquitination of IκBβ. J Biol Chem 1999;274:29591-29594.
86. Smit JJ, van Dijk WJ, El Atmioui D, Merkx R, Ovaa H, Sixma TK. Target specificity of the E3 ligase LUBAC for ubiquitin and NEMO relies on different minimal requirements. J Biol Chem 2013;288:31728-31737.
87. Rahighi S, et al. Specific recognition of linear ubiquitin chains by NEMO is important for NF-κB activation. Cell 2009;136:1098-1109.
88. Komander D, Reyes-Turcu F, Licchesi JD, Odenwaelder P, Wilkinson KD, Barford D. Molecular discrimination of structurally equivalent Lys 63-linked and linear polyubiquitin chains. EMBO Rep 2009;10:466-473.
89. Fujita H, et al. Mechanism underlying IκB kinase activation mediated by the linear ubiquitin chain assembly complex. Mol Cell Biol 2014;34:1322-1335.
90. Elliott PR, et al. Molecular basis and regulation of OTULIN-LUBAC interaction. Mol Cell 2014;54:335-348.
91. Schaeffer V, Akutsu M, Olma MH, Gomes LC, Kawasaki M, Dikic I. Binding of OTULIN to the PUB domain of HOIP controls NF-κB signaling. Mol Cell 2014;54:349-361.
92. Tokunaga F, et al. Specific recognition of linear polyubiquitin by A20 zinc finger 7 is involved in NF-κB regulation. EMBO J 2012;31:3856-3870.
93. Verhelst K, et al. A20 inhibits LUBAC-mediated NF-κB activation by binding linear polyubiquitin chains via its zinc finger 7. EMBO J 2012;31:3845-3855.
94. Boone DL, et al. The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses. Nat Immunol 2004;5:1052-1060.
95. Wertz IE, et al. De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-κB signalling. Nature 2004;430:694-699.
96. Tokunaga F. Linear ubiquitination-mediated NF-κB regulation and its related disorders. J Biochem 2013;154:313-323.
97. Damgaard RB, et al. The ubiquitin ligase XIAP recruits LUBAC for NOD2 signaling in inflammation and innate immunity. Mol Cell 2012;46:746-758.
98. Damgaard RB, et al. Disease-causing mutations in the XIAP BIR2 domain impair NOD2-dependent immune signalling. EMBO Mol Med 2013;5:1278-1295.
99. Abbott DW, Yang Y, Hutti JE, Madhavarapu S, Kelliher MA, Cantley LC. Coordinated regulation of Toll-like receptor and NOD2 signaling by K63-linked polyubiquitin chains. Mol Cell Biol 2007;27:6012-6025.
100. Deguine J, Barton GM. MyD88: a central player in innate immune signaling. F1000Prime Rep 2014;6:97.
101. Takeuchi O, Akira S. MyD88 as a bottle neck in Toll/IL-1 signaling. Curr Top Microbiol Immunol 2002;270:155-167.
102. Dubois SM, et al. A catalytic-independent role for the LUBAC in NF-κB activation upon antigen receptor engagement and in lymphoma cells. Blood 2014;123:2199-2203.
103. Deng L, et al. Activation of the IκB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell 2000;103:351-361.
104. Wertz IE, Dixit VM. Signaling to NF-κB: regulation by ubiquitination. Cold Spring Harbor Perspect Biol 2010;2:a003350.
105. Emmerich CH, et al. Activation of the canonical IKK complex by K63/M1-linked hybrid ubiquitin chains. Proc Natl Acad Sci USA 2013;110:15247-15252.
106. Skaug B, Jiang X, Chen ZJ. The role of ubiquitin in NF-κB regulatory pathways. Annu Rev Biochem 2009;78:769-796.
107. Gantke T, Sriskantharajah S, Sadowski M, Ley SC. IkappaB kinase regulation of the TPL-2/ERK MAPK pathway. Immunol Rev 2012;246:168-182.
108. Roget K, et al. IκB kinase 2 regulates TPL-2 activation of extracellular signal-regulated kinases 1 and 2 by direct phosphorylation of TPL-2 serine 400. Mol Cell Biol 2012;32:4684-4690.
109. Kumari S, et al. Sharpin prevents skin inflammation by inhibiting TNFR1-induced keratinocyte apoptosis. Elife 2014;3:e03422.
110. Rickard JA, et al. TNFR1-dependent cell death drives inflammation in Sharpin-deficient mice. Elife 2014;3:e03464.
111. Sheikh MS, Huang Y. Death receptor activation complexes: it takes two to activate TNF receptor 1. Cell Cycle 2003;2:550-552.
112. Cabal-Hierro L, Lazo PS. Signal transduction by tumor necrosis factor receptors. Cell Signal 2012;24:1297-1305.
113. Haas TL, et al. Recruitment of the linear ubiquitin chain assembly complex stabilizes the TNF-R1 signaling complex and is required for TNF-mediated gene induction. Mol Cell 2009;36:831-844.
114. Dynek JN, et al. c-IAP1 and UbcH5 promote K11-linked polyubiquitination of RIP1 in TNF signalling. EMBO J 2010;29:4198-4209.
115. Cho YS, et al. Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation. Cell 2009;137:1112-1123.
116. He S, et al. Receptor interacting protein kinase-3 determines cellular necrotic response to TNF-α. Cell 2009;137:1100-1111.
117. Zhang DW, et al. RIP3, an energy metabolism regulator that switches TNF-induced cell death from apoptosis to necrosis. Science 2009;325:332-336.
118. Lu TT, et al. Dimerization and ubiquitin mediated recruitment of A20, a complex deubiquitinating enzyme. Immunity 2013;38:896-905.
119. Shembade N, Ma A, Harhaj EW. Inhibition of NF-κB signaling by A20 through disruption of ubiquitin enzyme complexes. Science 2010;327:1135-1139.
120. Wu P, et al. The LEF1/CYLD axis and cIAPs regulate RIP1 deubiquitination and trigger apoptosis in selenite-treated colorectal cancer cells. Cell Death Dis 2014;5:e1085.
121. Mocarski ES, Upton JW, Kaiser WJ. Viral infection and the evolution of caspase 8-regulated apoptotic and necrotic death pathways. Nat Rev Immunol 2012;12:79-88.
122. Chen I, Ichinohe T. Response of host inflammasomes to viral infection. Trends Microbiol 2015;23:55-63.
123. Wen H, Miao EA, Ting JP. Mechanisms of NOD-like receptor-associated inflammasome activation. Immunity 2013;39:432-441.
124. Rodgers MA, et al. The linear ubiquitin assembly complex (LUBAC) is essential for NLRP3 inflammasome activation. J Exp Med 2014;211:1333-1347.
125. Yoneyama M, Onomoto K, Jogi M, Akaboshi T, Fujita T. Viral RNA detection by RIG-I-like receptors. Curr Opinion Immunol 2015;32C:48-53.
126. Paz S, et al. A functional C-terminal TRAF3-binding site in MAVS participates in positive and negative regulation of the IFN antiviral response. Cell Res 2011;21:895-910.
127. Belgnaoui SM, et al. Linear ubiquitination of NEMO negatively regulates the interferon antiviral response through disruption of the MAVS-TRAF3 complex. Cell Host Microbe 2012;12:211-222.
128. Liu S, et al. MAVS recruits multiple ubiquitin E3 ligases to activate antiviral signaling cascades. Elife 2013;2:e00785.
129. Inn KS, et al. Linear ubiquitin assembly complex negatively regulates RIG-I- and TRIM25-mediated type I interferon induction. Mol Cell 2011;41:354-365.
130. Zhao S, Ulrich HD. Distinct consequences of posttranslational modification by linear versus K63-linked polyubiquitin chains. Proc Natl Acad Sci USA 2010;107:7704-7709.
131. Pouwels J, et al. SHARPIN regulates uropod detachment in migrating lymphocytes. Cell Rep 2013;5:619-628.
132. Rantala JK, et al. SHARPIN is an endogenous inhibitor of beta1-integrin activation. Nat Cell Biol 2011;13:1315-1324.
133. Queisser MA, et al. HOIL-1L Functions as the PKCζ Ubiquitin Ligase to Promote Lung Tumor Growth. Am J Respir Crit Care Med 2014;190:688-698.
134. Pasparakis M, Vandenabeele P. Necroptosis and its role in inflammation. Nature 2015;517:311-320.
135. Davidovich P, Kearney CJ, Martin SJ. Inflammatory outcomes of apoptosis, necrosis and necroptosis. Biol Chem 2014;395:1163-1171.
136. Tamiya H, et al. IFN-γ or IFN-α ameliorates chronic proliferative dermatitis by inducing expression of linear ubiquitin chain assembly complex. J Immunol 2014;192:3793-3804.
137. Baeuerle PA, Henkel T. Function and activation of NF-κB in the immune system. Annu Rev Immunol 1994;12:141-179.
138. Lam KP, Rajewsky K. B cell antigen receptor specificity and surface density together determine B-1 versus B-2 cell development. J Exp Med 1999;190:471-477.
139. Yang Y, et al. Essential role of the linear ubiquitin chain assembly complex in lymphoma revealed by rare germline polymorphisms. Cancer Discov 2014;4:480-493.
140. Nilsson J, et al. Polyglucosan body myopathy caused by defective ubiquitin ligase RBCK1. Ann Neurol 2013;74:914-919.
141. Wang K, et al. Whole-genome DNA/RNA sequencing identifies truncating mutations in RBCK1 in a novel Mendelian disease with neuromuscular and cardiac involvement. Genome Med 2013;5:67.
142. MacDuff DA, et al. Phenotypic complementation of genetic immunodeficiency by chronic herpesvirus infection. Elife 2015;4:e04494.
143. Tomonaga M, et al. Activation of nuclear factor-κB by linear ubiquitin chain assembly complex contributes to lung metastasis of osteosarcoma cells. Int J Oncol 2012;40:409-417.
144. Mackay C, et al. E3 ubiquitin ligase HOIP attenuates apoptotic cell death induced by cisplatin. Cancer Res 2014;74:2246-2257.
145. Sakamoto H, et al. Gliotoxin suppresses NF-κB activation by selectively inhibiting linear ubiquitin chain assembly complex (LUBAC). ACS Chem Biol 2015;20:675-681.
146. Wild P, et al. Phosphorylation of the autophagy receptor optineurin restricts Salmonella growth. Science 2011;333:228-233.
147. Maruyama H, et al. Mutations of optineurin in amyotrophic lateral sclerosis. Nature 2010;465:223-226.
148. Rezaie T, et al. Adult-onset primary open-angle glaucoma caused by mutations in optineurin. Science 2002;295:1077-1079.